DelveInsight is a prominent provider of valuable research within biotech and pharmaceutical industries. It offers analytical reports in such Health Care sectors as gene therapy, medical oncologic therapy, Active Pharmaceutical Ingredient (API) manufacturing, stem cell medication, biosimilars, orphan drugs and others. The expertise includes:
- Company’s profile and licensing data;
- New technology studies;
- Biologic benchmarking;
- Treatment modality analysis;
- Competitive landscape;
- Product assessment; etc.
This knowledge is essential for Generic and Drug Development companies, which also receive drug sales estimation and product performance forecasts.
DelveInsight reconciles customers need for information and for innovative approaches in business development. Consequently, the obtained data is turned into strategic design, partner up opportunities, profit earning capacity of the business. DelveInsight analysts assist pharma enterprises in launching new products and marketing development of existing pharmaceutics.
Publications found:
6,889
Sort by:
Dopamine D2 receptor antagonist - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 Hours DelveInsight’s, “Dopamine D2 receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and...
January 2022
60 pages
GABA A receptor agonist - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 24 hours DelveInsight’s, “GABA A receptor agonist - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipe...
January 2022
60 pages
Interleukin-33 inhibitors - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 24 hours DelveInsight’s, “Interleukin-33 inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 7+ companies and 7+ pipe...
January 2022
60 pages
P selectin inhibitors - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 24 hours DelveInsight’s, “P selectin inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline...
January 2022
60 pages
Potassium channel antagonists - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 Hours DelveInsight’s, “Potassium channel antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10...
January 2022
60 pages
Serotonin receptor 2 angonist - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 24 Hours DelveInsight’s, “Serotonin receptor 2 Agonist - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 5+ p...
January 2022
60 pages
